BiotechTube

Tibulizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Sclerosis (SSc)

Conditions

Systemic Sclerosis (SSc), Scleroderma

Trial Timeline

Feb 6, 2025 → Jan 1, 2028

NCT ID
NCT06843239

About Tibulizumab

Tibulizumab is a phase 2 stage product being developed by Zura Bio for Systemic Sclerosis (SSc). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06843239. Target conditions include Systemic Sclerosis (SSc), Scleroderma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06843239Phase 2Recruiting

Competing Products

20 competing products in Systemic Sclerosis (SSc)

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 2
52
E6742EisaiPhase 1/2
41
KHK4827Kyowa KirinPhase 1
33
KHK4827 + PlaceboKyowa KirinPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + CyclophosphamideEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33

Other Products from Zura Bio

Tibulizumab Dose A + Tibulizumab Dose BPhase 2
44